Response to "Letter to the Editor Regarding a Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia"

被引：0
|
作者：
Mantelli, Flavio [1 ]
机构：
[1] Dompe Farmaceut SpA, Via Santa Lucia 6, I-20122 Milan, Italy
来源：
INFECTIOUS DISEASES AND THERAPY | 2023年 / 12卷 / 01期
关键词：
D O I：
10.1007/s40121-022-00727-4
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：301 / 302
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of Xiyanping injection in the treatment of COVID-19: A multicenter, prospective, open-label and randomized controlled trial
    Zhang, Xin-Yi
    Lv, Lang
    Zhou, Yu-Long
    Xie, Liang-Dong
    Xu, Qin
    Zou, Xiao-Fan
    Ding, Yan
    Tian, Jie
    Fan, Jia-Liang
    Fan, Hai-Wei
    Yang, Yi-Xi
    Ye, Xiao-Qun
    PHYTOTHERAPY RESEARCH, 2021, 35 (08) : 4401 - 4410
  • [42] Letter to the Editor Regarding "Safety and Efficacy of Noncompliant Balloon Angioplasty for the Treatment of Subarachnoid HemorrhageeInduced Vasospasm: A Multicenter Study"
    Yao, Zhong
    You, Chao
    WORLD NEUROSURGERY, 2017, 105 : 1022 - 1022
  • [43] TOCIVID-19-A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol
    Piccirillo, Maria Carmela
    Ascierto, Paolo
    Atripaldi, Luigi
    Cascella, Marco
    Costantini, Massimo
    Dolci, Giovanni
    Facciolongo, Nicola
    Fraganza, Fiorentino
    Marata, AnnaMaria
    Massari, Marco
    Montesarchio, Vincenzo
    Mussini, Cristina
    Negri, Emanuele Alberto
    Parrella, Roberto
    Popoli, Patrizia
    Botti, Gerardo
    Arenare, Laura
    Chiodini, Paolo
    Gallo, Ciro
    Salvarani, Carlo
    Perrone, Francesco
    CONTEMPORARY CLINICAL TRIALS, 2020, 98
  • [44] Response by Rothstein and Cucchiara to Letter Regarding Article, "Acute Cerebrovascular Events in Hospitalized COVID-19 Patients"
    Rothstein, Aaron
    Cucchiara, Brett L.
    STROKE, 2021, 52 (02) : E72 - E72
  • [45] Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial
    Firozabad, Amirreza Roostaei
    Meybodi, Zohreh Akhoundi
    Mousavinasab, Seyed Ruhollah
    Sahebnasagh, Adeleh
    Jelodar, Mohsen Gholinataj
    Karimzadeh, Iman
    Habtemariam, Solomon
    Saghafi, Fatemeh
    BMC INFECTIOUS DISEASES, 2021, 21 (01)
  • [46] Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial
    Amirreza Roostaei Firozabad
    Zohreh Akhoundi Meybodi
    Seyed Ruhollah Mousavinasab
    Adeleh Sahebnasagh
    Mohsen Gholinataj Jelodar
    Iman Karimzadeh
    Solomon Habtemariam
    Fatemeh Saghafi
    BMC Infectious Diseases, 21
  • [47] A Response to: Letter to the Editor Regarding Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort
    Belén Ruiz-Antorán
    Aránzazu Sancho-López
    Ferrán Torres
    Ana Fernández-Cruz
    Infectious Diseases and Therapy, 2021, 10 : 1811 - 1813
  • [48] A Response to: Letter to the Editor Regarding Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort
    Ruiz-Antoran, Belen
    Sancho-Lopez, Aranzazu
    Torres, Ferran
    Fernandez-Cruz, Ana
    INFECTIOUS DISEASES AND THERAPY, 2021, 10 (03) : 1811 - 1813
  • [49] Response to letter to the editor about the comparison of CT findings between outpatient and hospitalized COVID-19 patients
    Zarei, Fariba
    Zeinali-Rafsanjani, Banafsheh
    JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES, 2022, 53 (01) : 186 - 187
  • [50] Efficacy and Safety of Therapeutic Versus Prophylactic Dose of Anticoagulation in Hospitalized Patients with Severe COVID-19 Pneumonia and Coagulopathy: An Open-Label, Randomized Controlled Trial
    Adrian, L. H.
    Hutomo, S. A.
    Negari, A. D. S.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (0F)
12345